Alcon Announces US Launch of Voyager DSLT for Glaucoma

Alcon announced Feb. 19 the full US commercial launch of the Voyager laser for direct selective laser trabeculoplasty (DSLT).

The company said attendees of the American Glaucoma Society meeting in Washington, DC, from Feb. 26 through March 2, would be able to try the Voyager DSLT at the Alcon booth.

The laser gained CE marking in May 2022 and US FDA 510(k) clearance in December 2023. The Voyager is a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, intended for use in performing DSLT, a new automated, noncontact, one-second trabeculoplasty procedure.

Alcon, a Swiss company with US headquarters in Fort Worth, Texas, acquired the Voyager with its purchase of Israel’s Belkin Vision in 2024.

The advantages to DSLT over traditional treatment options include the laser energy being delivered directly through the limbus to the trabecular meshwork without the need for a gonioscopy lens or laser delivery across the anterior chamber. In addition, the device automatically defines the target location and applies the laser treatment sequence, while the eye tracker compensates for any eye movement.

SLT serves as a relatively safe and effective treatment that can reduce a glaucoma patient’s medication load without much risk. Recent studies, including the LiGHT study, discuss the benefits of using SLT treatment as a first-line therapy, including long-term cost savings and improved patient compliance.